alk patient
Complete the form to get the full interpretation guide 

VENTANA ALK (D5F3) CDx Assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORI® (crizotinib), ZYKADIA® (ceritinib), ALECENSA® (alectinib) or LORBRENA® (lorlatinib).

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.  

This product is intended for in vitro diagnostic (IVD) use.

Empower your lab to provide timely results that lead to confident decisions with: 

  • Easy binary scoring 
  • Fully automated, 4 1/2-hour turnaround time 
  • Brightfield vs. fluorescent staining
Form Successfully Submitted!
Thank you for your submission!

We value your privacy.

Want to learn more?
VENTANA ALK (D5F3) CDx Assay: Indentifying ALK+ NSCLC Patients for Targeted Treatment

Learn more about NSCLC and how to identify patiences who may be appropriate for ALK+ targeted treatment.

Roche Diagnostics University

Find online training courses for the VENTANA ALK (D5F3) CDx Assay. Topics include indentifying ALK+ NSCLC patients for targeted treatment. 

testing sites
Find a testing site offering the VENTANA ALK (D5F3) CDx Assay